Presentation on theme: "Priority Setting and Effectiveness Patrick Osewe, MD, MPH World Bank"— Presentation transcript:
1 Priority Setting and Effectiveness Patrick Osewe, MD, MPH World Bank Introduction
2 Learning ObjectivesIntroduce economic and ethical issues surrounding different care interventionsShare experience in prioritizing eligible populations for access to ARTUnderstand different policy options for scaling up access to ARV drugsUnderstanding the constraints to scaling up care and support services in AfricaShare experience on how to averting possible negative consequences of scaled up treatmentLearning/Training ObjectivesTo introduce participants to economic and ethical issues surrounding different care interventions.To outline and explain fair process in prioritizing eligible populations for access to ART.To define and facilitate understanding of the different policy options for scaling up access to ARV drugs. To explain some of the constraints to scaling up access to care in developing countries.To discuss ways of averting possible consequences of scaled up treatment.
3 Prioritizing Programs of Care for People with HIV/AIDS What considerations are made when deciding what kind of treatment to offer for people with HIV/AIDS?EconomicAnalysisUnit 9 examines issues related to prioritizing programs of care for people with HIV/AIDS.DemandEthicsTechnicalChallengesAcceptabilityBio-medicalneedPoliticalPressure
4 Ethical Principles that are Related to Priority Setting JusticeHuman rights and dignityThe common goodFair opportunityEthical PrinciplesJustice is the moral virtue of constant and firm willingness to give to one's neighbor that which is his or her due. Justice promotes fair, equitable, and appropriate treatment in light of what is owed to the individual.Human dignity is the principle that accepts that humans deserve a certain standard of respect, free from needless degradation.The common good demands that actions be taken that benefit the community.Beneficence includes any form of action to benefit another.Fair opportunity is the rule of social distribution that attempts to decrease unjust forms of allocation
5 Care Options for People with HIV/AIDS in Africa Ways of improving the quality of life for people with HIV and AIDS in Africa includePalliative care: providing supportive care and pain controlProphylactic care against opportunistic infectionsTreatment of opportunistic infectionsAntiretroviral therapyCost Effectiveness of Care Programs for People with HIV/AIDSDALY= Disability Adjusted Life YearCEA is used to assess and summarize the relative value of an intervention.This is done by measuring both the costs and the consequences of several choices of intervention that are intended to meet the same objective.In a CEA, a researcher establishes the effectiveness of the program according to expected health impact (disability adjusted life years or cases of HIV averted can be used).
6 Costs of Palliative Care for People with HIV/AIDS in Africa Author (Year)Country/ DescriptionCost (US$)World Bank (1997)Sub-Saharan Africa/ palliative care plus treatment of inexpensive OIs$ per patient yearUys and Hensher (2002)South Africa/ drugs and nursing care$400 per patient yearAIDS palliative careThis slide outlines findings from two studies from sub-Saharan Africa that assessed HIV palliative care and their associated costs. The goal of AIDS palliative care is to alleviate pain and other symptoms, provide appropriate nourishment and hydration, and prepare for a peaceful death.
7 Costs of Prophylaxis for OIs for People with HIV/AIDS in Africa Prophylaxis for Opportunistic InfectionsAuthor (Year)Country/ DescriptionCost (US$)Wiktor et al. (1999)Cote d'Ivoire/ co-trimoxazole preventive therapy$1.50 per monthBell et al. (1999)Sub-Saharan Africa/ preventive therapy for tuberculosis and treatment of adverse reactions$38.31 for 6 monthsSlide 10: Relevant SlideProphylactic careThis slide outlines findings from studies from sub-Saharan Africa that assessed preventative care using Co-trimoxazole and TB drugs and their associated costs.OIs are associated with mortality independent of CD4 count and their occurrence may accelerate Treatment of infections before symptoms are present is referred to as prophylactic care.
8 Costs and Cost-Effectiveness of Treatment of Opportunistic Infections in People with HIV/AIDS in AfricaTreatment of Opportunistic InfectionsAuthor (Year)Country/ DescriptionCost (US$)World Bank (1997)Sub-Saharan Africa/ treatment of PCP or toxoplasmosis$8 per patient treatmentSub-Saharan Africa/ treatment of tuberculosis$37 per patient treatmentFloyd et al. (1997)Uganda/ Directly observed treatment short course (DOTS)DOTS: $ per patient treatmentSlide 11: Relevant SlideTreatment of OIsCosts and cost-effectiveness (DALYs gained) of treatment of OIs, once a person is shows signs and symptoms of the OI, are outlined in this slide.
9 Costs and Cost-Effectiveness of HAART for People with HIV/AIDS in Africa Reducing Viral Load: HAARTAuthor (year)Country/ DescriptionCost (US$)Creese et al.2002Senegal and Cote d’Ivoire$ 1100 per year(Cost/DALY= $1100)Wood et al. 2000South Africa$ 350 per year(Cost/DALY= $1800)Slide 12: Relevant SlideHAARTCosts and cost-effectiveness (DALYs gained) of HAART are outlined in this slide.
10 Potential Priority Populations for the Distribution of ART What considerations are made when deciding which populations are offered ART first?EconomicProductivityUnit 10 examines potential priority populations for the distribution of ART.SocialProductivityFair processLikelihoodofadherencePotential fortransmissionFirst ComeFirst ServedCommunityInvolvement
11 Potential Priority Populations for the Distribution of ART The IssuesDeciding on who should be the first recipients of ARVsWhat process must be followed in priority setting for fairness?What Criteria? - Policy guidance on populations to be prioritizedInvolving Communities in decision makingThis slide examines potential priority populations for the distribution of ART Fair Process must be followed in priority settingCriteria need to be formed that guide policy on which populations should be prioritizedCommunities should be involved in decision making
12 What are the Elements of Fair Process? TransparencyCommunity access to the rationale for decisions madeRelevant reasoning is discussed among stakeholdersRoom for revising the criteriaAccountability for enforcing the criteria are adhered toThis slide outlines some suggested criteria for fair process.
13 Who are the Potential Recipients of Scaled up ARV Programs First Come/First ServedGroups of People Based on CharacteristicsThe economically or socially productive sectorThe poorThose likely to adhere to therapyHealth care workersUsing ARV Drugs to Prevent HIV TransmissionExposed health care workers and rape victimsHIV infected mothers (PMTCT)Those at risk of transmitting HIVSex workers/High risk menThis slide outlines a number of possible methods for arriving at priority populations for HAARTPriority may be assessed based on First Come/First Served; Social, behavioral or bio-medical characteristics; or their ability to Prevent further HIV Transmission
14 Prioritization to Receive ARVs: The Poor IssuesIdentifying the poorCost of testing for HIVCost of out-patient visitsIlliteracyPoor nutritionCost of treating all HIV+ people below the poverty line in India: $280 per year of life savedPrioritizing the PoorThis slide outlines issues associated with prioritizing the poor for subsidized HAART programs.Even if antiretroviral drugs were to be provided free of charge, other costs would also need to be considered. These include: ELISA tests to establish HIV status; counseling; out-patient visits to monitor side-effects and to issue supplies of drugs; and laboratory tests. Funds would also have to be sought from others to finance other costs such as importation of supplies from outside of the country (which are likely to be more expensive) and the strengthening of laboratories (in order to be able to sustainable provide high-quality tests). Difficulties faced in this population such as illiteracy and poor nutrition may also need to be considered. Cost of treating all HIV+ people below the poverty line in India: $280 per year of life saved
15 Prioritization to Receive ARVs: The Economically or Socially Productive IssuesIdentifying the economically or socially productiveSome may be able to afford the drugs without subsidization (issues of fairness)Likely to be literate and able to support other associated costs of carePrioritizing those who are believed to be contributing most to the societyThe contribution can be through either through economic or social means. It could be argued that prolonging life and improving health in certain segments of the society, everyone will benefit everyone.
16 Preventing the spread of HIV Using ARVs ARVs have demonstrated reductions in transmission when used forOccupational post- exposure prophylaxisThe prevention of mother-to-child transmissionARVs are likely to reduce HIV transmission by reducing viral load, thereby making HIV less sexuallytransmissiblePrioritizing based on the potential to prevent further transmissionARV programs have the potential to prevent HIV transmission (to health care workers, victims of rape and babies of HIV positive mothers). In the general population, HAART prolongs and improves life but is not curative. The effect of using treatment as a population-level HIV prevention strategy is uncertain.
17 Post-Exposure Prophylaxis (PEP) for Occupational Exposure Risk of HIV transmission after a needle stick injury from an HIV infected source is about 1 in 400 (or 0.25%)Zidovudine (AZT) lowers the risk of HIV transmission from a needle stick exposure by 80%PEP may result in cost savings in developing countriesThis slide outlines the risk after exposure to HIV though needle stick or mucus membranesThe risk of HIV transmission after a needle stick injury exposure involving body fluid from an HIV infected source about one in 400 or 0.25% and about 0.09% after mucus membrane exposure (Ippolito et al., 1993). A US case-control study reported that zidovudine (AZT) lowered the risk of HIV transmission from a needle stick exposure by about 80% (Cardo et al., 1997).
18 Post-Exposure Prophylaxis (PEP) for Post-Rape Unprotected heterosexual sex between HIV discordant couples = estimated risk of 0.2% (if the male partner is HIV+)Risk of acquiring HIV from unprotected receptive anal sex with an infected partner is estimated to be 0.8 %Risk of HIV infection in a rape situation would likely be higher asThere is a greater potential for other sexually transmitted diseases, trauma, and inflammation.The risk is multiplied as more assailants are involvedThis slide outlines the risk after exposure to HIV though rapeUnprotected heterosexual sex between HIV discordant couples carries an estimated risk of 0.2% if it is the male partner who is infected (Anderson & May, 1988). The risk of acquiring HIV from unprotected receptive anal sex with an infected partner is estimated to be 0.8 % (Vittinghoff et al., 1999).
19 Prevention of Mother-to-Child Transmission The infection rates of children born to HIV infected mothers in the absence of any intervention is about 25%Several studies have demonstrated that short courses of AZT or Nevirapine during pregnancy, reduce transmission by 50%This slide outlines the risk after exposure to HIV though mother to child (vertical) transmissionThe infection rates of children born to HIV infected mothers in the absence of any intervention is about 25% (Wiktor et al., 1999). Several studies have demonstrated that short courses of zidovudine (AZT) or nevirapine during pregnancy, sometimes in combination with other antiretrovirals, reduce transmission by as much as 50% in low-income countries depending on whether the mothers breast-fed and the type of regimen given (DeCock et al., 2000; Jackson et al., 2003; Taha et al., 2002). This intervention is extremely inexpensive. One effective combination is being used in Cameroon at a total cost of less than US $23 (Ayouba et al, 2003).One effective combination is being used in Cameroon at a total cost of less than $US 23
20 Supplying ARVs to those Most at Risk for Spreading HIV: Population-level Prevention ARVs canreduce the viral load of HIV, a major determinant of HIV transmissionpotentially be used to prevent the spread of HIV at a population levelIf ARV treatment is shown to effectively reduce sexual transmission, who should get them?Viral Load? HIV transmission ?This slide outlines the potential of HAART to reduce sexual transmissionMost studies conclude that HAART reduces the viral load of HIV-1, which is a major determinant of HIV-1 transmission from infected to uninfected people (Quinn et al., 2000). There is the potential to use ARVs to prevent the spread of HIV at a population level. If we assume that ART will effectively reduce sexual transmission, then a program could be designed to prevent the spread of HIV at the population level. In order to effectively slow or reverse epidemic growth, HIV viral load would need to be reduced in those people who are most at risk of spreading HIV. HIV positive people who are engaging in the riskiest sexual behavior could be targeted for an intervention to reduce HIV in the general population.?
21 Avoiding the Pitfalls: Ways to Improve the Effectiveness of ART Programs SideEffectsDisinhibitionResistanceMonitoringUnit 11 examines ways to avoid the pitfalls of scaling up programs using ARV drugs and ways to improve the effectiveness of those initiatives.HIVpreventionAdherence
22 Avoiding the Pitfalls: Ways to Improve the Effectiveness of ART Programs ARVs have the potential to benefit populations greatlyPossible adverse effects exist such asincreases in risky behaviorResistanceside-effectsover-reliance on ARVsUnit 11 examines ways to avoid the pitfalls of scaling up programs using ARV drugs and ways to improve the effectiveness of those initiatives.
23 Adverse Behavioural Change - 1 Even with effective viral suppression due to HAART, infection can occur33% of men on ARVs continue to shed virus in their semenTransmission benefits gained from a program covering 50-90% of HIV positive people with effective HAART is reversed with a 10% increase in risky behaviourActual coverage with HAART does not usually exceed 30% of HIV positive people in industrialized countriesTransmissibility even with viral suppressionThis slide describes how even with effective viral suppression due to HAART, transmission can occur
24 Adverse Behavioural Change - 2 Risky behaviour is on the rise among MSM in North America in the post-HAART eraFor years, North American MSM had declining rates of HIV and STI. Some cities in the late 1990’s reported an upturn in both epidemics, especially among young MSMIn Kenya, on two separate occasions immediately following wide media coverage of “quack cures”, 100% condom use among female sex workers decreased condom use and increased HIV incidenceAdverse behavior changeRisky behavior on the rise among MSM in North America in the post-HAART eraFor years, North American MSM had declining rates of HIV and STI - some cities in the late 1990’s reported an upturn in both epidemicsThis change in behaviour may be more pronounced among young MSM
25 Adverse Behavioural Change - 3 PEARL OMEGAKEMRON%This slide outlines ways to mitigate against adverse behaviour changeHealthy media messages that encourage both positive living and reinforce safe sexual behaviour can assist with reducing the effects of disinhibition that often accompany HIV care. Cost-effective, evidence-based interventions such as peer interventions with sex workers and high risk men should be scaled up at the same level as the ART programs. Consideration should be made as to which groups in society are prioritised to receive subsidised or free treatment as a potentially preventative intervention.YearSource: Jha et al., 2001
26 Mitigating Against Adverse Behavior Change Step up prevention activities that are highly effectiveHealthy media messagesPositive living, but with scaled up preventive behaviorCounseling: encourage safe behavior and adherence to therapyThis slide outlines ways to mitigate against adverse behaviour changeHealthy media messages that encourage both positive living and reinforce safe sexual behaviour can assist with reducing the effects of disinhibition that often accompany HIV care. Cost-effective, evidence-based interventions such as peer interventions with sex workers and high risk men should be scaled up at the same level as the ART programs. Consideration should be made as to which groups in society are prioritised to receive subsidised or free treatment as a potentially preventative intervention. Encourage adherence to therapy to promote decreases in viral load and probably reduce the risk of transmission of HIV.
27 Side Effects - 1Most HIV-infected people on HAART experience some side effectsA study from Botswana found that the side effects were so serious that they interfered with adherence to therapy in 9% of people on HAARTPoor management of side effects may lead to purposeful non-adherence, which in turn could lead to lowered effectiveness of the treatment and resistanceThis slide emphasises the prevalence of side effects and reasons for their occurrence. Most HIV-infected people on HAART experience some side effects. A study from Botswana found that the side effects were so bad that they interfered with adherence to therapy in 9% of people on HAART (Weiser et al., 2003).
28 Side Effects - 2 Side effects from HAART include the following Bone demineralizationHyperlipidemiaHyperglycemiaGastrointestinal symptomsDiarrheaRashesHeadachesNeuropathiesHepatotoxicityLactic acidosisHypersensitivityPancreatitisAnemiaNeutropeniaThis slide lists the side effects HAARTSide effects from HAART include bone demineralization, hyperlipidemia, hyperglycemia, gastrointestinal symptoms, diarrhea, rashes, headaches, hepatotoxicity, lactic acidosis, hypersensitivity, neuropathies, pancreatitis, anemia, and neutropenia (Lesho et al., 2003). Poor management of side effects may lead to purposeful non-adherence, which in turn could lead to lowered effectiveness of the treatment and resistance.
29 Mitigating Against Side Effects Make a number of standard regimens of medications availableTreat side-effects. Offer good overall care, not just drugsEncourage adherence to therapyOffer appropriate nutritional supportThis slide outlines ways to mitigate against side-effectsMake a number of combinations of medications available.Treat side-effects. Offer good overall care, not just drugs.Encourage adherence to therapy.Offer appropriate nutritional support (high fat/ high protein foods).
30 Resistance to ARVs - 1There is a concern that there will be widespread antiretroviral resistance resulting in mass treatment failureOne of the key accelerators of resistance is lack of adherenceA study from Botswana found that only 54% of people on ARVs reported that they had adhered to the therapy regimenA Ugandan study reported that 70% of patients enrolled in their study had virus that was resistant to at least one antiretroviral drugDrug resistant HIV strains are transmissibleThis slide outlines issues related to ARV drug resistanceDistribution of drugs without resistance testing and/or lack of adequate supply of drugs may cause widespread antiretroviral resistance resulting in mass treatment failure (Naglekerke et al., 2002; DeVlas et al., 2002). Resistance may occur in part due to lack of adherence (Sethi et al., 2003). A study from Botswana found that only 54% of people on ARVs reported that they had adhered to the therapy regimen (Weiser et al., 2003). A Ugandan study reported that 70% of patients enrolled in their study had virus that was resistant to at least one antiretroviral drug (Weildle, 2000). Drug resistant HIV strains are transmissible (Chesney et al., 1999).
31 Resistance to ARVs-2“HAART for all” may lead to resistance in drug regimens which are used to prevent mother-to-child transmissionNevirapine should be reserved for mother to child treatmentMother to child transmission programs are threatenedThis slide outlines the issue of one of the major consequences that will occur if widespread ARV resistance occurs.Antiretroviral drugs administered before and during birth and while breastfeeding prevent transmission of HIV-1 from mothers to their babies (Scotland et al., 2003). There is a possible that “HAART for all” may lead to resistance in drug regimens which to prevent mother-to-child transmission. Reserving one class of ARV (nevirapine) for mother to child treatment may alleviate some of the pressure on the virus that causes resistance.*Note that only an estimated 5% of HIV infected mothers in developing countries currentlyhave access to ARVs
32 Mitigating Against Drug Resistance Use standard regimens with fixed dose therapiesMonitor drug resistance using simplified diagnosticsImprove clinical management and build infrastructureWork with communities to find strategies that encourage adherence to therapyIf treatment regimens are not followed, there is a greater opportunity for drug resistant strains of HIV to develop. Resistant viruses are transmitted from person to person. ART programs are more likely to remain effective if the standard regimens with fixed dose therapies are used. Training of health care workers and key community members can improve clinical management. Better health care infrastructure will allow for a more consistent supply of medications. When scaling up ART interventions, partner with communities to find strategies that encourage adherence to therapy. Drug resistance can be monitored using simplified diagnostics.
33 ConclusionPolicies written to guide ARV programs must address the followingthe level of treatment to be offeredthe process to be followed in prioritizationthose who will be prioritised for treatmentthe potential adverse effectshow those side-effects can be mitigated againstConclusion